Y
Yves Pommier
Researcher at National Institutes of Health
Publications - 847
Citations - 65543
Yves Pommier is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Topoisomerase & DNA. The author has an hindex of 123, co-authored 789 publications receiving 58898 citations. Previous affiliations of Yves Pommier include Purdue University & Kyushu University.
Papers
More filters
Journal ArticleDOI
Synthesis and biological evaluation of new fluorinated and chlorinated indenoisoquinoline topoisomerase I poisons.
Daniel E. Beck,Wei Lv,Monica Abdelmalak,Caroline B. Plescia,Keli Agama,Christophe Marchand,Yves Pommier,Mark Cushman +7 more
TL;DR: A hydroxyethylaminopropyl side chain on the lactam nitrogen of two halogenated indenoisoquinoline Top1 inhibitors was found to also impart inhibitory activity against tyrosyl DNA phosphodiesterases 1 and 2 (TDP1 and TDP2), which are enzymes that participate in the repair of DNA damage induced by Top1 poisons.
Journal ArticleDOI
New Insights on the Genetics of Pheochromocytoma and Paraganglioma and Its Clinical Implications
Sakshi Jhawar,Yasuhiro Arakawa,Suresh Kumar,Diana Varghese,Yoo Sun Kim,Nitin Roper,Fathi Elloumi,Yves Pommier,Karel Pacak,Jaydira Del Rivero +9 more
TL;DR: The most recent advances in the field of genetics are presented, including the new genetic insights of PPGLs and the latest guidelines on the surveillance of asymptomatic SDHx mutation carriers.
Journal ArticleDOI
Characterization of DNA topoisomerase I in three SN-38 resistant human colon cancer cell lines reveals a new pair of resistance-associated mutations
Niels Frank Jensen,Keli Agama,Amit Roy,Amit Roy,David Hersi Smith,Thomas D. Pfister,Maria Unni Rømer,Maria Unni Rømer,Hongliang Zhang,James H. Doroshow,James H. Doroshow,Birgitta R. Knudsen,Jan Stenvang,Nils Brünner,Yves Pommier +14 more
TL;DR: It was underlined that cross-resistance to the new indenoisoquinoline drugs depends on the specific underlying molecular mechanism of resistance to SN-38, and it was added to the growing knowledge about resistance mechanisms for Top1-targeting chemotherapeutic drugs.
Journal ArticleDOI
Synthesis and evaluation of new antitumor 3-aminomethyl-4,11-dihydroxynaphtho[2,3-f]indole-5,10-diones.
Andrey E. Shchekotikhin,Andrey E. Shchekotikhin,Valeria A. Glazunova,Lyubov G. Dezhenkova,Yuri N. Luzikov,V. N. Buyanov,Helena M. Treshalina,Nina A. Lesnaya,Vladimir I. Romanenko,Dmitry N. Kaluzhny,Jan Balzarini,Keli Agama,Yves Pommier,Alexander A. Shtil,Maria N. Preobrazhenskaya +14 more
TL;DR: 3-aminomethyl derivatives of 4,11-dihydroxynaphtho[2,3-f]indole-5,10-dione emerge as a new prospective chemotype for the search of antitumor agents.
Journal ArticleDOI
The structure-activity relationships of A-ring-substituted aromathecin topoisomerase I inhibitors strongly support a camptothecin-like binding mode.
Maris A. Cinelli,Andrew Morrell,Thomas S. Dexheimer,Keli Agama,Surbhi Agrawal,Yves Pommier,Mark Cushman +6 more
TL;DR: Eight novel series of A-ring-substituted aromathecins are synthesized, through a simple, modular route, as part of a comprehensive SAR study, and this considerable SAR overlap lends further support to the hypothesis that aromathcins bind in the Top1 cleavage complex as interfacial inhibitors in a 'camptothecin-like' pose.